Literature DB >> 8061416

Quantitative detection of neutralizing antibodies against polioviruses and non-polio enteroviruses (NPEV) using an automated microneutralization assay: a seroepidemiologic survey.

B Weber1, H Rabenau, J Cinatl, G Maass, H W Doerr.   

Abstract

A seroepidemiological survey for the assessment of immunity against polioviruses and non-polio enteroviruses (NPEV) seroprevalence was performed using a recently established automated microneutralization assay. The seroprevalences of neutralizing antibodies against Coxsackie viruses B1-B6, and A9, echoviruses 6, 9, 11, and 30, and polioviruses 1, 2, and 3 were investigated in serum samples collected over a period of 30 months (January 1990 to June 1992). Overall, NPEV seroprevalence ranged from 8.3% (Coxsackie virus B6) to 69.8% (echovirus 30). Age-related increases of seroprevalence were only observed for Coxsackie viruses B2 and A9. Relatively low antibody titres were found, the average antibody titre being the highest for Coxsackie virus B2 (1/55.4). The overall poliovirus seropositivity rate reached 80%. The highest seroprevalence was observed in the higher age groups (> or = 50 years). A relatively high proportion (7%) of individuals did not show neutralizing antibodies against all the three poliovirus serotypes. The results of our study have shown that, using an automated microneutralization assay, it is possible to perform seroepidemiological surveys in large patient populations. Until now, no comparable study concerning the NPEV seroprevalence has been performed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061416     DOI: 10.1016/s0934-8840(11)80515-3

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  8 in total

1.  Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students.

Authors:  Sabine Wicker; Holger F Rabenau; René Gottschalk; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Microbiol Immunol       Date:  2007-02-02       Impact factor: 3.402

2.  Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany.

Authors:  Holger F Rabenau; Matthias Richter; Hans Wilhelm Doerr
Journal:  Med Microbiol Immunol       Date:  2009-11-26       Impact factor: 3.402

3.  Seroepidemiology of echovirus 30 in Korean children.

Authors:  Joo Young Lee; Yumi Seo; Ui Yoon Choi; Jong-Hyun Kim; Jin Han Kang
Journal:  World J Pediatr       Date:  2017-08-02       Impact factor: 2.764

4.  Poor immunity status against poliomyelitis in medical students: a semi-anonymous study.

Authors:  Manuel Külshammer; Ute Winke; Monika Frank; Ursula Skali-Lami; Henrike Steudel; Gert Schilling; Jan Felix Drexler; Anna Maria Eis-Hübinger; Bertfried Matz
Journal:  Med Microbiol Immunol       Date:  2012-06-13       Impact factor: 3.402

5.  Deficiency of immunity to poliovirus type 3: a lurking danger?

Authors:  Claudia Reinheimer; Imke Friedrichs; Holger F Rabenau; Hans W Doerr
Journal:  BMC Infect Dis       Date:  2012-01-26       Impact factor: 3.090

6.  A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people.

Authors:  Hye-Jin Kim; Seoyeon Hwang; Somin Lee; Yunhyung Kwon; Kwangsook Park; Young Joon Park; Geun-Ryang Bae; Sang Won Lee; Yong-Seok Jeong; Ji-Yeon Hyeon
Journal:  BMC Infect Dis       Date:  2015-03-28       Impact factor: 3.090

Review 7.  Is EU/EEA population protected from polio?

Authors:  Dre Nijsten; P Carrillo-Santisteve; A Miglietta; J Ruitenberg; P L Lopalco
Journal:  Hum Vaccin Immunother       Date:  2015-04-21       Impact factor: 3.452

8.  Seroepidemiology of enterovirus D68 infection in China.

Authors:  Zichun Xiang; Linlin Li; Lili Ren; Li Guo; Zhengde Xie; Chunyan Liu; Taisheng Li; Ming Luo; Gláucia Paranhos-Baccalà; Wenbo Xu; Jianwei Wang
Journal:  Emerg Microbes Infect       Date:  2017-05-10       Impact factor: 7.163

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.